Men's Health Videos
Men's Health Latest News
Meta-analysis shows that use of medication is associated with an 18% lower risk.
Just over 41% of patients eligible for active surveillance by European standards were found to have undergraded prostate cancer.
Focal and whole-gland approaches may provide alternatives for recurrent PCa after radiotherapy
Patients who received the drug as part of their treatment survived longer than those on placebo by a median 4.4 months.
Researchers find no increased risk of adverse pathologic outcomes among men who put off radical prostatectomy for up to 12 months.
Patients with hemophilia, however, do have a higher incidence of cancers overall.
Men who take phosphodiesterase type 5 inhibitors after radical prostatectomy are more likely to experience biochemical recurrence of disease.
In patients who received the graft, average return to continence and potency was 1.21 months and 1.34 months, respectively.
A Turkish study found that 55% of male coronary artery disease patients had some degree of erectile dysfunction.
Potency was observed in 51% of unilateral surgery patients and 71% of bilateral surgery patients who received oral therapy.
Patients reported significantly less pain with pelvic plexus block than conventional periprostatic block.
African-American and Caucasian men have similar tumor burden, treatment choices, and survival.
Nerve-sparing surgery by robot-assisted laparoscopy was associated with a 2.4 times increased odds of regaining potency versus open surgery
Longer cancer-specific and overall survival seen in older men with locally advanced or high-risk PCa
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)